🌟 Pharmidex is proud to attend the Creative Disruption Forum! 🌟
December 11, 2024
We are excited to participate in the Creative Disruption Forum: How Tech is Changing Small Molecule Drug Hunting, taking place on Thursday, 12 December at MAYDE, 5-10 Brandon Road, London N7 9AA.
Representing
Pharmidex will be our Head of Operations,
Ash Alavijeh, and
Mohammed Yaqoob, from Business Development. They are looking forward to engaging with all attendees to explore opportunities for future collaborations with companies, research groups, and universities.
This forum is an incredible opportunity to connect, share ideas, and discuss how technological innovation is revolutionizing small molecule drug discovery. Let’s shape the future of science together! 🚀
We would be delighted to meet you there. Feel free to reach out or stop by for a chat!
We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜
We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.
We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.
